<DOC>
	<DOCNO>NCT02052427</DOCNO>
	<brief_summary>This prospective , randomize , placebo-controlled , double blind safety efficacy clinical trial .</brief_summary>
	<brief_title>Safety &amp; Efficacy Adipose-Derived Regenerative Cells Treatment Chronic Myocardial Ischemia ( ATHENA II )</brief_title>
	<detailed_description>To assess safety efficacy Adipose-Derived Regenerative Cells ( ADRCs ) deliver via intramyocardial route treatment chronic ischemic heart disease patient eligible percutaneous surgical revascularization .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1 . Males females &gt; 20 &lt; 80 year age 2 . Significant multivessel coronary artery disease amenable percutaneous surgical revascularization 3 . CCS Angina Functional Class IIIV and/or NYHA Stages Heart Failure Class II III 4 . On maximal medical therapy anginal symptom and/or heart failure symptoms 5 . Hemodynamic stability ( SBP ≥ 90 mm/Hg , HR &lt; 110 ) 6 . Ejection fraction ≥ 20 % ≤ 45 % 7 . Inducible ischemia use objective assessment ischemia within 1 year screening ( i.e . exercise ECG change , SPECT ) 8 . Left ventricular wall thickness ≥ 8 mm target site cell injection 1 . Atrial fibrillation flutter without pace maker guarantee stable heart rate 2 . Unstable angina 3 . LV thrombus , document echocardiography 4 . Planned stag treatment CAD intervention heart 5 . Platelet count &lt; 100,000/mm3 6 . WBC &lt; 2,000/mm3 7 . TIA stroke within 90 day prior randomization 8 . ICD shock within 30 day prior randomization 9 . Any condition require immunosuppressive medication 10 . A highrisk acute coronary syndrome ( ACS ) myocardial infarction 60 day prior randomization 11 . Revascularization within 60 day prior randomization 12 . Inability walk treadmill except class IV angina patient evaluate separately 13 . Hepatic dysfunction , define aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal range ( x ULN ) 14 . Hemoglobin ≤ 10.0 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ischemic heart disease</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>adult stem cell</keyword>
	<keyword>adipose derive regenerative cell</keyword>
</DOC>